

Supplementary Material

Efficacy, Safety, and Pharmacoeconomic Analysis of Adalimumab and Secukinumab for Moderate-to-Severe Plaque Psoriasis: A Single-Center, Real-World Study

Gaojie Li, Yuanxia Gu, Qin Zou, Yiyi Wang, Yue Xiao, Dengmei Xia, Tongying Zhan, Xingli Zhou, Qian Wang, Wei Yan, Wei Li

G. Li

Department of Dermatology and Venereology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China; Department of Dermatovenereology, Chengdu Second People's Hospital, Chengdu 610011, Sichuan, China

Y. Gu, Y. Wang, Y. Xiao, X. Zhou, Q. Wang

Department of Dermatology and Venereology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China

Q. Zou

West China School of Nursing, Sichuan University, Chengdu 610041, Sichuan, China

D. Xia

Department of Dermatology, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan, China

T. Zhan

Department of Dermatology, Women's and Children's Hospital Affiliated to Medical College of Chengdu University of Electronic Science and Technology/Chengdu Women's and Children's Central Hospital, Chengdu, Sichuan 610073, China

Corresponding Authors:

W. Li

Department of Dermatology and Venereology, Rare Diseases Center, West China
Hospital, Sichuan University, Chengdu 610041, Sichuan, China

Email: liweihx_hxyy@scu.edu.cn


W. Yan

Department of Dermatology and Venereology, Rare Diseases Center, West China
Hospital, Sichuan University, Chengdu 610041, Sichuan, China


Email: yanweihappyhappy@163.com

Fig. S1

(a)



(b)



(c)




Table S1

Element	<i>P</i>	<i>OR (95%CI)</i>
Sex	0.60	0.52(0.14-1.98)
Age	0.03	0.27(0.08-0.89)
BMI(kg/m ²)	0.12	0.92(0.82-1.04)
Duration of psoriasis(years)	0.39	1.04(0.97-1.11)
PASI score at baseline	0.20	1.07(0.97-1.17)
PsA	0.98	1.22(0.33-4.58)
Smoking	0.60	1.61(0.47-5.50)
Family history	0.10	0.61(0.16-2.35)
Drinking	0.52	0.42(0.12-1.46)
Previous use of biologic therapy	0.88	1.34(0.27-6.70)
Previous conventional and biologic treatment	0.77	1.34(0.29-6.14)
Current biotherapeutics(SEC vs ADA)	<0.01	6.23(2.41-16.10)

Pharmacoeconomic reevaluation

Based on current drug prices after our study, the price of adalimumab(ADA) is 1,290.00 Chinese yuan(CNY) each and secukinumab(SEC) is 1,188.00 CNY each. The medical insurance reimbursement ratio is calculated as an average of 70%.

We compared the cost and percentage of PASI75 responders of two biologics, and conducted three cost-effectiveness analyses based on the following three aspects: i) the original price of the drugs during 2019-2020 when ADA was included in medical insurance, while SEC was not; ii) the current price of the drugs when SEC and ADA are both included in medical insurance reimbursement; iii) the current price of the drugs with an average reduction of 70% after medical reimbursement.(Table S2)

We can conclude that ADA is more cost-effective than SEC in the three situations. But as drug prices and health care policies change, the cost-effective ratio of the two biologics tends to be close.

Table S2

During the study			Current			
			Before reimbursement		After reimbursement	
	SEC	ADA	SEC	ADA	SEC	ADA
	(n=85)	(n=46)	(n=85)	(n=46)	(n=85)	(n=46)
C (CNY)	41,972.00	10,320.00	16,632.00	10,320.00	4,989.60	3,096.00
E (%)	90.59	58.70	90.59	58.70	90.59%	58.70
C/E (CNY)	46,311.83	17,580.92	18,359.64	17,580.92	5,507.89	5,274.28